Cheuk To Chung
Cheuk To Chung has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Gary Tse
School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China
15 shared publications - Bernard Man Yung Cheung
University of Hong Kong
14 shared publications - Jiandong Zhou
Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
14 shared publications - Tong Liu
Second Hospital of Tianjin Medical University
14 shared publications - Wing Tak Wong
The Chinese University of Hong Kong
14 shared publications - Catherine Po Ling Chan
Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China
13 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S7: Falsification analysis: Exposure effects of SGLT2I v.s. DPP4I on new onset lower limb fracture (ICD-9 codes: 820–829) in the matched cohort after 1:1 propensity score matching.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S7: Falsification analysis: Exposure effects of SGLT2I v.s. DPP4I on new onset lower limb fracture (ICD-9 codes: 820–829) in the matched cohort after 1:1 propensity score matching.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Figure S3: Procedures of data processing for the 3-arm analysis. This figure shows the adverse events after initial exposure of SGLT2I, DPP4I, and GLP1a in the database, for a three-arm analysis using stabilized IPTW.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Figure S3: Procedures of data processing for the 3-arm analysis. This figure shows the adverse events after initial exposure of SGLT2I, DPP4I, and GLP1a in the database, for a three-arm analysis using stabilized IPTW.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S3: Baseline and clinical characteristics of SGLT2I, DPP4I and GLP1a patients in the 3-way analysis
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S3: Baseline and clinical characteristics of SGLT2I, DPP4I and GLP1a patients in the 3-way analysis
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S6: Sensitivity analysis: Analysing the outcome in the full cohort without propensity score matching.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S6: Sensitivity analysis: Analysing the outcome in the full cohort without propensity score matching.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S1: The International Classification of Diseases, Clinical Modification (ICD-9-CM and ICD-10) codes for definitions of past comorbidities and outcomes.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S1: The International Classification of Diseases, Clinical Modification (ICD-9-CM and ICD-10) codes for definitions of past comorbidities and outcomes.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Figure S1: Propensity score matching comparisons and proportional hazard assumption checking with parallel lines for SGLT2I versus DPP4I before and after 1:1 matching with nearest neighbours search strategy with calliper of 0.1.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Figure S1: Propensity score matching comparisons and proportional hazard assumption checking with parallel lines for SGLT2I versus DPP4I before and after 1:1 matching with nearest neighbours search strategy with calliper of 0.1.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S8: Number of events and incidence of NPC and H&N cancer of all users and metformin users from Hong Kong diabetes patient diagnosed in 2009.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S8: Number of events and incidence of NPC and H&N cancer of all users and metformin users from Hong Kong diabetes patient diagnosed in 2009.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S4: Sensitivity analysis: Three-arm (only SGLT2I, only DPP4I, and only GLP1a) analysis results using stabilized IPTW, new onset nasopharyngeal cancer, other head & neck cancer, cancer related mortality in the matched cohort (1:1).
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S4: Sensitivity analysis: Three-arm (only SGLT2I, only DPP4I, and only GLP1a) analysis results using stabilized IPTW, new onset nasopharyngeal cancer, other head & neck cancer, cancer related mortality in the matched cohort (1:1).
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Data from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Nasopharyngeal carcinoma (NPC) remains a major endemic disease in parts of Asia especially Southern China and Southest Asia, the risk factors of which are distinct from other head and neck cancers. Antidiabetic drugs have been proposed to reduce the risk of NPC. The associations between sodium–glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and head and neck cancer among patients with type 2 diabetes mellitus (T2DM) remain unknown. This was a population-based cohort study including patients with T2DM treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. Propensity score matching (1:1 ratio) was performed using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. The primary outcome was new-onset NPC and other head and neck cancers. We found that patients with T2DM were treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. This cohort included 75,884 patients with T2DM, among whom 28,778 patients were on an SGLT2I and 47,106 patients were on a DPP4I. After matching (57,556 patients), 106 patients developed NPC and 50 patients developed head and neck cancer. Compared with DPP4Is, SGLT2Is were associated with lower risks of NPC (HR, 0.41; 95% confidence interval, 0.21–0.81) but not of head and neck cancer (HR, 1.00; 95% confidence interval, 0.26–3.92) after adjustments. The association remained consistent in different risk models, matching approaches, and sensitivity analysis. In conclusion, this study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM, whereas their biological effects need future confirmation.Prevention Relevance:This study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM. SGLT2Is should be considered before DPP4Is about the risks of NPC in regions with high prevalence of NPC.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Nasopharyngeal carcinoma (NPC) remains a major endemic disease in parts of Asia especially Southern China and Southest Asia, the risk factors of which are distinct from other head and neck cancers. Antidiabetic drugs have been proposed to reduce the risk of NPC. The associations between sodium–glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and head and neck cancer among patients with type 2 diabetes mellitus (T2DM) remain unknown. This was a population-based cohort study including patients with T2DM treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. Propensity score matching (1:1 ratio) was performed using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. The primary outcome was new-onset NPC and other head and neck cancers. We found that patients with T2DM were treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. This cohort included 75,884 patients with T2DM, among whom 28,778 patients were on an SGLT2I and 47,106 patients were on a DPP4I. After matching (57,556 patients), 106 patients developed NPC and 50 patients developed head and neck cancer. Compared with DPP4Is, SGLT2Is were associated with lower risks of NPC (HR, 0.41; 95% confidence interval, 0.21–0.81) but not of head and neck cancer (HR, 1.00; 95% confidence interval, 0.26–3.92) after adjustments. The association remained consistent in different risk models, matching approaches, and sensitivity analysis. In conclusion, this study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM, whereas their biological effects need future confirmation.Prevention Relevance:This study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM. SGLT2Is should be considered before DPP4Is about the risks of NPC in regions with high prevalence of NPC.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S2: Sensitivity analyses for exposure effects of SGLT2I v.s. DPP4I on new onset nasopharyngeal cancer, new onset salivary gland and other head/neck cancer, cancer related mortality, all-cause mortality in the matched cohort using different models.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Nasopharyngeal Carcinoma and Head and Neck Cancer in Type 2 Diabetes after SGLT2I, DPP4I, and GLP1a Use
Supplementary Table S2: Sensitivity analyses for exposure effects of SGLT2I v.s. DPP4I on new onset nasopharyngeal cancer, new onset salivary gland and other head/neck cancer, cancer related mortality, all-cause mortality in the matched cohort using different models.